HHP/HPH COVID-19 Community Webinar Series

Thursday, January 13, 2022 5:30pm – 6:30pm

HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS

1



Moderator

Andy Lee, MD Medical Director, Hawai'i Health Partners

HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS

Disclaimer:

- The following is intended as information resource only for HHP/HPH providers, clinicians, administrative and clinical leaders.
- Specific areas may not pertain directly to your clinical practice area and/or may not be applicable to your practice based on your existing workflows, infrastructure, software (e.g. EHR), and communications processes.

Webinar Information

- You have been automatically muted. You cannot unmute yourself.
- You will be able to submit questions via the Q&A section.
 - Due to time constraints, any unanswered questions will be addressed this week and posted on the HHP website
- A recording of the meeting will be available tomorrow on the HHP website and intranet.

How to Claim CME Credit

1. Step 1: Confirm your attendance

 You should have completed a brief questionnaire before joining today's live webinar.

2. Step 2: HPH CME team will email you instructions

- Complete and submit evaluation survey that will be emailed to you within one week of the offering.
- Your CE certificate will be immediately available to you upon completion of your evaluation.
- Questions? Email
 <u>hphcontinuingeduc@hawaiipacifichealth.org</u>



CME Accreditation Statement

- In support of improving patient care, Hawai'i Pacific Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
- Hawai'i Pacific Health designates this webinar activity for a maximum of 1.0 AMA PRA Category 1 Credit (s) ™ for physicians. This activity is assigned 1.0 contact hour for attendance at the entire CE session.



JOINTLY ACCREDITED PROVIDER™

INTERPROFESSIONAL CONTINUING EDUCATION



Disclosures

 The planners and presenters of this activity report no relationships with companies whose products or services (may) pertain to the subject matter of this meeting

7



EHRER

ABORATORY



Omicron – a new and rapidly spreading Variant of SARS-CoV-2

Dr. rer. nat. Axel T. Lehrer, Associate Professor

Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School of Medicine University of Hawai'i at Manoa Honolulu, Hawaii








- First detected in South Africa in mid November 2021
- Described in an article in Nature on 25th November 2021
- Declared a variant of concern on November 26th, 2021 (WHO)
- WHY?
- More than 50 mutations, 30 in the spike protein







Wrapp and Wang et al. Science 2020



Class I fusion glycoprotein on the surface of the virus responsible for to gain entry into host cells using the cell receptor human ACE2

The S protein is a trimeric protein that exists in a metastable prefusion


~180 kDa if fully glycosylated, 22 glycosylation sites

> Omicron carries significant modifications on the spike protein including in the furing cleavage site, NTD and may increase binding affinity to ACE2 (as seen with Delta)














Genetic Distance of Omicron to other Variants



A long new branch



Where did 'weird' Omicron come from? Kupferschmidt K. Science (2021); 374(6572):1179.



Today – in Nature...



OMICRON MAKES A FEEBLE ATTACK ON THE LUNGS

Animal studies suggest that the variant's inability to multiply in lung tissue could make it less dangerous.

By Max Kozlov

arly indications from South Africa and the United Kingdom signal that the fast-spreading Omicron variant of the coronavirus SARS-CoV-2 is less dangerous than its predecessor Delta. Now, a series of laboratory studies offers a tantalizing explanation for the difference: Omicron does not infect cells deep in the lung as readily as it does those in the upper airways.

The observation "might explain what we see in patients", says Melanie Ott, a virologist at the Gladstone Institute of Virology in San Francisco, California. But she adds that Omicron's hyper-transmissibility means that hospitals are filling quickly – despite potential decreases in the severity of the disease it causes.

Authorities in South Africa announced on 30 December that the country had passed its Omicron peak without a major spike in deaths. And a 31 December UK government report said that people in England who were infected with Omicron were about half as likely to require hospitalization or emergency care as were those infected with Delta.

But the number of people who have gained immune protection against COVID-19 through

vaccination, infection or both has grown over time, making it difficult to determine whether Omicron intrinsically causes milder disease than do earlier variants. For answers, researchers have turned to the laboratory.

Michael Diamond, a virologist at Washington University in St. Louis, Missouri, and his colleagues infected rodents with Omicron and other variants to track disease progression. The differences were staggering: after a few days, the concentration of virus in the lungs of animals infected with Omicron was at least ten times lower than in rodents infected with other variants¹. Other teams have also noted that, compared with previous variants, Omicron is found at reduced levels in lung tissue^{2,3}. Diamond was especially shocked to see that the Omicron-infected animals nearly maintained their body weight, whereas the others quickly lost weight - a sign that their infections were causing severe disease. The lungs are where the coronavirus does much of its damage, and lung infection can set off an inflammatory immune response that ravages both infected and uninfected cells. Fewer infected lung cells could mean milder illness.

Another group found that Omicron is much less successful than previous variants at infecting lung cells and miniature lung models called might find it easy to hitch a ride on material expelled from the nose and mouth, allowing the virus to find new hosts, says Gupta.

The latest results could mean that "the virus establishes a very local infection in the upper airways and has less chance to go and wreak havoc in the lungs", Ott says. That would be welcome news – but a host's immune response plays an important part in disease severity, and scientists need more clinical data if they are to understand how Omicron's basic biology influences its disease progression in humans.

Omicron's course of infection could also have implications for children, says Audrey John, a specialist in paediatric infectious disease at the Children's Hospital of Philadelphia in Pennsylvania. Young children have relatively small nasal passages, and babies breathe only through their noses. Such factors can make upper respiratory conditions more serious for children than for adults, John says. But she adds that she has not seen data suggesting an uptick in the numbers of young children hospitalized for conditions that could indicate a severe infection of the upper respiratory tract.

Although there is still much to learn about the new variant, Gupta says that fears raised in late November by the multitude of mutations in Omicron's genome have not been completely borne out. He says the initial alarm offers a cautionary tale: it's difficult to predict how a virus will infect organisms from its genetic sequence alone.

- Diamond, M. et al. Preprint at Research Square https://doi. org/10.21203/rs.3.rs-1211792/v1 (2021).
- McMahan, K. et al. Preprint at bioRxiv https://doi. org/10.1101/2022.01.02.474743 (2022).
- Bentley, E. G. et al. Preprint at bioRxiv https://doi. org/10.1101/2021.12.26.474085 (2021).
- Meng, B. et al. Preprint at bioRxiv https://doi. org/10.1101/2021.12.17.473248 (2021).
- Peacock, T. P. et al. Preprint at bioRxiv https://doi. org/10.1101/2021.12.31.474653 (2022).
- Willett, B. J. et al. Preprint at medRxiv https://doi. org/10.1101/2022.01.03.21268111 (2022).

Nature | Vol 601 | 13 January 2022 | 177

All in Preprints...


- Diamond, M. et al. Preprint at Research Square https://doi. org/10.21203/rs.3.rs-1211792/v1 (2021).
- McMahan, K. et al. Preprint at bioRxiv https://doi. org/10.1101/2022.01.02.474743 (2022).
- Bentley, E. G. et al. Preprint at bioRxiv https://doi. org/10.1101/2021.12.26.474085 (2021).
- Meng, B. et al. Preprint at bioRxiv https://doi. org/10.1101/2021.12.17.473248 (2021).
- Peacock, T. P. et al. Preprint at bioRxiv https://doi. org/10.1101/2021.12.31.474653 (2022).
- Willett, B. J. et al. Preprint at medRxiv https://doi. org/10.1101/2022.01.03.21268111 (2022).





Viral Characteristics of Omicron






- Different plaque morphology
 = less induction of syncytia
- Different tissue tropism

Peacock, T. P. *et al.* Preprint at bioRxiv https://doi. org/10.1101/2021.12.31.474653 (2022).



Viral Characteristics of Omicron





When cultured 1:1 Delta and Omicron show different dominance in cells from upper and lower respiratory tract


Peacock, T. P. *et al.* Preprint at bioRxiv https://doi. org/10.1101/2021.12.31.474653 (2022).






Viral Characteristics of Omicron








Delta variant is more dependent on functional proteases in the upper respiratory tract, Omicron develops Tolerance rapidly

Peacock, T. P. *et al.* Preprint at bioRxiv https://doi. org/10.1101/2021.12.31.474653 (2022).










McMahan, K. *et al.* Preprint at bioRxiv https://doi. org/10.1101/2022.01.02.474743 (2022).














- 10⁵ PFU Beta (HP01542)
 10⁵ PEU Delta (HW(5250)
- 10⁵ PFU Delta (UW-5250)
- 10⁵ PFU B.1.1.529

- 10⁵ PFU Epsilon (VRLC009)
- 10⁵ PFU lota (PV26425)
- 10⁵ PFU Mu (80384)
- 10⁵ PFU Lambda (SEC0506)


Reduced pathology is also seen in mouse models and replicated independently in a second hamster model (Michael Diamond lab)

Diamond, M. *et al.* Preprint at Research Square https://doi. org/10.21203/rs.3.rs-1211792/v1 (2021).










Diamond, M. et al. Preprint at Research Square https://doi. org/10.21203/rs.3.rs-1211792/v1 (2021).

OMICRON B.1.1.529-infected




B.1.1.529-infected



Representative micro-CT axial and coronal images of the lungs of mock-infected (n = 3) or B.1.617.2-(n = 4) and B.1.1.529-infected (n =4) hamsters on 7 dpi. Lung abnormalities included multifocal nodules (black arrows). ground glass opacity (white arrowheads), and regions of lung consolidation (white arrows) that were peripheral, bilateral, and multilobar Pneumomediastinum is indicated with white asterisks.








Significantly lower virus neutralization of Omicron variant is observed in vaccinees immunized with various vaccines

Willett, B. J. *et al.* Preprint at medRxiv https://doi. org/10.1101/2022.01.03.21268111 (2022).

Mutations in Omicron Spike cause reduced Neutralization






mRNA as a booster increases neutralization, especially in individuals previously receiving an adenovirus-vectored vaccine

Willett, B. J. et al. Preprint at medRxiv https://doi. org/10.1101/2022.01.03.21268111 (2022).



Temporal Aspects of Time since Vaccination





Japanese study (mRNA vaccines) – interval since vaccination matters


Miyamoto S. *et al.* Preprint at medRxiv https://doi. org/10.1101/2021.12.28.21268481 (2022).





Temporal Aspects of Time since Vaccination






Miyamoto S. *et al.* Preprint at medRxiv https://doi. org/10.1101/2021.12.28.21268481 (2022).







All vaccinees show an improved response to vaccine boosters and a greater boost than subsequent COVID-19 infection


Garcia-Beltran, W.F. et al. **Cell**, *in press* (2022) DOI: 10.1016/j.cell.2021.12.033

Pacific Center for Emerging Infectious Diseases Research + Tropical Infectious Diseases Detection and Prevention Program



Booster effect on Neutralization






Garcia-Beltran, W.F. et al. **Cell**, *in press* (2022) DOI: 10.1016/j.cell.2021.12.033











COVID-19 Treatment Updates

Douglas Kwock, MD

Vice President, Medical Staff Affairs Hawai'i Pacific Health

HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS

Outpatient COVID-19 Therapeutic Options

- Monoclonal antibodies
 - Sotrovimab
- Antiviral agents
 - Oral
 - Paxlovid
 - Molnupiravir
 - -IV
 - Remdesivir



- Bamlanivimab
- Bamlanivimab/Etesevimab
- Regen-CoV (Casarivimab/Imdevimab)

Omicron!



United States: 10/3/2021 - 1/8/2022 ** ** 100% 90% B.1.617.2 80% 617.2 70% m 60% B.1.617.2 B.1.617.2 B.1.617.2 B.1.617.2 B.1.617.2 B.1.617.2 B.1.617.2 B.1.617.2 3.1.617.2 3.1.617.2 50% 40% 30% 20% 10% 0% 0/16/21 .0/23/21 .1/13/21 .1/20/21 11/27/21 12/11/21 12/18/21 12/25/21 1/1/22 1/8/22 10/9/21 10/30/21 11/6/21 12/4/21

12/4/21: 0.6%

- 12/11/21: 7.5%
- 12/18/21: 39.4%
- 12/25/21: 71.6%

HAWAIʻI

PACIFIC

HEALTH

HAWAI'I


HEALTH PARTNERS

- 1/1/22: 92.3%
 - 1/8/22: 98.3%





Estimate of proportion of variants circulating in the State of Hawaii



PACIFIC

HEALTH

HEALTH PARTNERS

State of Hawai'i sequencing and variant report for SARS-CoV-2, 2021-12-29

\$	BAM ‡	ETE ≑	BAM/ETE 🗘	CAS ≑	IMD ‡	CAS/IMD ≑	CIL ≑	TIX ≑	CIL/TIX 🗘	SOT ≑	REG ≑
Alpha	1 ₁₃	16 ₁₁	1.2 ₄	1 ₁₉	0.7 ₁₉	18	1.0 ₈	1.7 ₇	0.8 5	2.3* ₁₅	2.6 ₂
Beta	>1000 ₁₅	313 ₁₃	>1000 ₅	76 ₂₃	0.6 ₂₂	1.3 ₁₁	1.1 ₇	6.3 ₇	1.3 ₅	1 ₁₄	33 ₃
Gamma	>1000 ₁₁	294 ₁₁	252	200 17	0.4 ₁₆	1 5	0.5 7	6.4 ₆	0.7 2	1.3 ₁₂	61 ₃
Delta	>1000 ₁₂	0.5 ₁₂	1 2	0.7 ₁₃	1.5 ₁₃	1 ₃	3.5 ₄	0.8 4	0.6 2	1.3 ₈	9.8 ₃
Omicron	>1000 ₁₂	294 ₁₁	501 ₄	>1000 ₁₃	500 ₁₃	>1000 ₆	336 ₁₂	735 ₁₂	100 7	4.9 ₁₂	>1000 ₅
lota	>1000 ₅	1.4 ₅	21 ₂	11 4	1.2 ₄	1.2 ₂	0.9 ₂	8.1 ₂	-	0.8 4	-
Epsilon	>1000 4	14	10 ₂	1.3 ₂	1.7 ₂	1	3	-	-	0.7 3	43 ₄
Kappa	>1000 ₅	0.9 ₄	5.5 ₂	6 ₅	1.3 ₄	1 ₃	4.7	0.7	2	0.7 ₃	24
N501Y	1.1 ₅	3.1 ₈	1	1 ₉	0.8 ₉	0.8 3	1.1 ₅	1.3 ₄	1.0 ₂	1.7* ₈	5.5
E484K	>1000 4	2.9 ₇	24	13 ₁₃	1 ₁₃	1.9 ₇	1.5 ₄	4.6 ₄	3.2 ₂	0.4 7	8.7
K417N	0.5 4	761 ₉	-	7 ₉	0.7 ₉	1.3 ₄	0.6 5	0.4 4	0.4 2	0.6 7	-
L452R	>1000 2	1 5	5	1 5	2 6	2.5 4	-	-	-	0.6	35
T478K	1.7 ₂	0.8 ₂	-	1.9 ₂	1.5 ₂	2.6	1 ₂	1.5	-	1 ₃	1
N439K	1.3	0.4 3	-	0.8 5	28 ₆	1.8	-	-	-	1 ₃	-
Y453F	1.6 ₂	1.7 ₄	-	310 ₈	1.5 ₇	3.5	-	-	-	1.1	-
F490S	293 ₂	1.1 ₂	-	0.8 3	1.2 ₃	0.6 ₂	-	-	-	0.8 ₂	-
S494P	86 ₂	0.6 ₂	-	3.5 ₄	1.2 ₃	0.9	-	-	-	2 ₂	-

https://covdb.stanford.edu/page/susceptibility-data/



Monoclonal Antibodies: Sotrovimab

Emergency use authorization

- Mild-to-moderate COVID-19
- Patients \geq 12 years of age and weighing \geq 40kg
- Positive results of direct SARS-CoV-2 test
- High risk for progression to severe COVID-19
- Start within 10 days of symptoms onset
- Administered IV, single dose
- Not for:
 - Hospitalized for COVID-19
 - Require oxygen or an increase in baseline oxygen due to COVID-19



Oral Antiviral Agents: Paxlovid & Molnupiravir

- Emergency use authorization
 - Mild-to-moderate COVID-19
 - Patients
 - Paxlovid: Patients \geq 12 years of age and weighing \geq 40 kg
 - Molnupiravir: Patients \geq 18 years of age
 - Positive results of direct SARS-CoV-2 test
 - At high risk for progression to severe COVID-19
 - Start within 5 days of symptom onset
 - Not for:
 - Hospitalized for COVID-19
 - Pre-exposure or post-exposure prophylaxis
 - Use longer than 5 days



Oral Antiviral Agents

Paxlovid	Molnupiravir				
Pfizer	Merck				
 Nirmatrelvir SARS-CoV-2 protease inhibitor 150mg tablet Ritonavir HIV-1 protease inhibitor and CYP3A inhibitor 100mg tablet 	 Nucleoside analog inhibits SARS- CoV-2 replication by viral mutagenesis 200mg capsules 				
88% reduction in hospitalization & death	30% reduction in hospitalization & death				
Patients ≥ 12 years of age and weighing ≥ 40 kg	Patients ≥ 18 years of age				
 3 tablets (2 nirmatrelvir/1 ritonavir) Twice daily for 5 days	4 capsulesTwice daily for 5 days				



Oral Antiviral Agents: Paxlovid

Renal impairment

- Mild renal (eGFR ≥60 to <90 mL/min)
 - No dosage adjustment
- Moderate renal (eGFR ≥30 to <60 mL/min)</p>
 - 150mg nirmatrelvir (1 tab) and 100mg ritonavir (1 tab)
 - Twice daily for 5 days
 - Prescriptions should specify the numeric dose of each active ingredient
- Severe renal impairment (eGFR <30 mL/min)
 - NOT recommended



Oral Antiviral Agents: Paxlovid

Hepatic impairment

- Mild (Child-Pugh Class A)
 - No dosage adjustment
- Moderate (Child-Pugh Class B)
 - No dosage adjustment
- Severe hepatic (Child-Pugh Class C)
 - NOT recommended



Oral Antiviral Agents: Paxlovid

Drug-Drug interactions

- NIH Covid-19 Treatment Guidelines: Panel's Statement on Potential Drug-Drug Interactions Between ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications
 - <u>https://files.covid19treatmentguidelines.nih.gov/guidelines/section</u>/<u>section_164.pdf</u>

Lots!



Prescribe an alternative COVID-19 therapy for patients who are receiving any of the medications listed.	 Before prescribing ritonavir-boosted nirmatrelvir (Paxlovid), determine whether the patient is receiving any of the medications listed. If the patient is receiving any of these medications, withhold the medication if clinically appropriate. If withholding is not clinically appropriate, use an alternative concomitant medication or COVID-19 therapy.^a 		
Amiodarone	Alfuzosin	1	
Apalutamide	Alprazolam		
Bosentan	Atorvastatin		
Carbamazepine	• Avanafil		
Cisapride	Clonazepam		
Clopidogrel	Codeine		
Clozapine	Cyclosporine ^b		
· Colchicine in patients with renal and/or hepatic impairment	• Diazepam		
Disopyramide	• Everolimus ^b		
Dofetilide	Fentanyl		
Dronedarone	Hydrocodone		
Eplerenone	Lomitapide		
Ergot derivatives	Lovastatin		
Flecainide	Meperidine (pethidine)		
Flibanserin	Midazolam (oral)		
Glecaprevir/pibrentasvir	Oxycodone		
Ivabradine	Piroxicam		
Lumateperone	Propoxyphene		
Lurasidone	Rosuvastatin		
Mexiletine	Salmeterol		
Phenobarbital	Sildenafil for erectile dysfunction		
Phenytoin	Silodosin		
Pimozide	Simvastatin		
Propafenone	• Sirolimus ^b		
Quinidine	Suvorexant		
Ranolazine	• Tacrolimus ^b		
Rifampin	Tadalafil for erectile dysfunction		
Rifapentine	Tamsulosin		
Rivaroxaban	Tramadol		
 Sildenafil for pulmonary hypertension 	• Triazolam		
St. John's wort	Vardenafil		
 Tadalafil for pulmonary hypertension 			
Ticagrelor		AWAI'I	11.61.674
• Vorapaxar			11/ \\ \ /
		ACIFIC	HEAL

PARTNERS

HEALTH

Oral Antiviral Agents: Molnupiravir

- May cause fetal harm
 - Pregnancy
 - NOT recommended
 - Childbearing potential
 - Effective contraception during treatment and for 4 days after the final dose
- May affect bone and cartilage growth
 NOT for use in < 18 years of age



IV Antiviral Agents: Remdesivir

- Approved on 10/22/2020
 - Patients \geq 12 years of age and weighing \geq 40 kg
 - Requiring hospitalization

NIH recommendation

- Off-label use for outpatient treatment
- Start within 7 days of symptom onset
- 200mg IV on day 1, 100mg IV on day 2 and 3

Outpatient Treatment of COVID-19

INTERIM Clinical Guidance on Therapeutics for Outpatient Treatment of COVID-19 (updated January 7, 2022)




1

In order of preference

- 1. Paxlovid
- 2. Sotrovimab
- 3. Remdesivir
- 4. Molnupiravir





December 30, 2021

² COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies is authorized for the treatment of COVID-19 in patients with immunosuppressive disease in either the outpatient or inpatient setting (COVID-19 Convalescent Plasma EUA)

HAWAIʻI

PACIFIC

HEALTH

HAWAI'I

HEALTH

PARTNERS

https://www.phe.gov/emergency/events/COVID19/therapeutics/Documents/COVID-Therapeutics-Decision-Aid.pdf

Outpatient Treatment of COVID-19

Tier	Risk Group
1	 Immunocompromised individuals not expected to mount an adequate immune response to COVID-19 vaccination or SARS-CoV-2 infection due to their underlying conditions, regardless of vaccine status (see Immunocompromising Conditions below); or Unvaccinated individuals at the highest risk of severe disease (anyone aged ≥75 years or anyone aged ≥65 years with additional risk factors).
2	 Unvaccinated individuals at risk of severe disease not included in Tier 1 (anyone aged ≥65 years or anyone aged <65 years with clinical risk factors)
3	 Vaccinated individuals at high risk of severe disease (anyone aged ≥75 years or anyone aged ≥65 years with clinical risk factors) Note: Vaccinated individuals who have not received a COVID-19 vaccine booster dose are likely at higher risk for severe disease; patients in this situation within this tier should be prioritized for treatment.
4	 Vaccinated individuals at risk of severe disease (anyone aged ≥65 years or anyone aged <65 with clinical risk factors) Note: Vaccinated individuals who have not received a COVID-19 vaccine booster dose are likely at higher risk for severe disease; patients in this situation within this tier should be prioritized for treatment.

INTERIM **Clinical Guidance on Therapeutics for Outpatient Treatment of COVID-19** (updated January 7, 2022) ******* Healthcare Association

1



Pre-Exposure Prophylaxis

Evusheld

- Monoclonal antibodies: Tixagevimab & Cilgavimab
- Pre-exposure prophylaxis of COVID-19
 - Not currently infected with SARS-CoV-2
 - Have not had a known recent exposure
- Patients \geq 12 years of age and weighing \geq 40 kg
- Patients
 - Moderate to severe immune compromise and may not mount an adequate immune response to COVID-19 vaccination OR
 - Vaccination with any available COVID-19 vaccine is not recommended
- Pre-exposure prophylaxis with Evusheld is NOT a substitute for vaccination




Outpatient Treatment of COVID-19

- Resources will be uploaded to intranet and HHP website (COVID-19 Therapeutics folder)
 - EUAs
 - INTERIM Clinical Guidance on Therapeutics for Outpatient Treatment of COVID-19
 - Updated HPH COVID-19 Treatment Protocol



HPH Facility Capacity & Cases



David Underriner

Executive Vice President of Oahu Operations

Chief Executive Officer of Kapiolani Medical Center for Women & Children, Pali Momi Medical Center and Straub Medical Center,

Hawaii Pacific Health



Jen H. Chahanovich President & Chief Executive Officer of Wilcox Medical Center Chief Executive Officer of Kauai Medical Clinic

HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS

Monoclonal Antibodies (MOAB) and Respiratory Evaluation Clinic (REC)



Sandra Noon, DO

Primary Care Physician – Internal Medicine, Mililani Family Health Center

Chief of Primary Care Hawai'i Pacific Health Medical Group

> HAWAI'I PACIFIC HEALTH

48

HAWAI'I

HEALTH

PARTNERS

HPH Respiratory Evaluation Clinics

For COVID-19 Evaluation

- Patients who need in-person evaluation for COVID-19 symptoms, illness, etc.
- Not to be used as a site for COVID-19 testing, unless your patient is at high risk of progressing to severe disease.

Straub Respiratory Evaluation Clinic

- Monday-Friday, 8:30 a.m.-4 p.m.
- 826 S. King St., 2nd floor
- 808-462-5100

Kaua'i Medical Clinic Respiratory Evaluation Clinic

- Monday-Friday, 8:30 a.m. to 4:30 p.m.
- 3-3420 Kuhio Highway, Suite B
- (Pediatric Isolation Room located between Wilcox Medical Center and Kaua'i Medical Clinic)
- Lihu'e, HI 96766
- 808-245-1504 or walk-in

HPH COVID-19 Virtual Clinic for Video and Phone Visits

- The HPH COVID-19 Virtual Clinic can be reached by calling 808-462-5430 (press option 3).
- The hours of operation are 8 a.m. to 8 p.m. daily.

CREATING A HEALTHIER HAWAI'I

ΗΔW/ΔΙΊ

HEALTH

PARTNERS

HAWAI

PACIFIC

ΗΓΔΙΤΗ

Pediatric Options to Treat Patients with or Suspected to have COVID-19

Kapi'olani Pediatric Outpatient Clinic

HPH Medical Group pediatricians will see patients, newborns up to age 18, with viral symptoms when their PCP determines that an in-person visit is required. Hours of operation are Monday-Friday, 1:30 p.m.-5 p.m. This is located on the 3rd floor of the Diamond Head Tower in the Multidisciplinary Clinic. Providers with pediatric patient referrals should call 808-763-2888 to make an appointment. Please note, this clinic is not for testing only. COVID-19 testing should continue to be scheduled through the testing centers.

• Kapi'olani Pediatric After-Hours Clinic

- The Pediatric After-Hours Clinic at Kapi'olani is open for in-person appointments, virtual appointments or walk-ins. Hours of operation are Monday-Friday, 5-8 p.m.; and Saturday-Sunday, Noon-7 p.m. It is located on the 1st floor in the Pediatric Outpatient Clinic. Children experiencing fever and respiratory symptoms (cough or difficulty breathing) or concerns associated with COVID-19 can walk-in with no appointment necessary to be seen by one of our pediatric health care professionals.
- For more information, or to schedule an appointment with either the Pediatric Outpatient Clinic or the Pediatric After-Hours Clinic, call 808-763-2888 from 8 a.m.-8 p.m.



Monoclonal Antibody (MoAb) - Sotrovimab


- HPH receives limited doses of the monoclonal antibody, sotrovimab, which is approved via EUA for treatment of active, mild/moderate COVID-19 infection (including the omicron variant).
- Priority is given to Tier 1 and 2 Patients (e.g. immunocompromised patients, ≥ 75, or ≥ 65 with clinical risk factors). Patients should be 12 years or older and weigh at least 40kg. Patients who are hospitalized OR requiring oxygen therapy due to COVID-19 are *ineligible* to receive sotrovimab.
- Administration should be completed as soon as possible following a positive PCR/NAAT COVID-19 test and within 10 days of symptom onset.
- If your patient is experiencing mild/moderate COVID-19 symptoms **and** meets the criteria, please discuss the risks and benefits of sotrovimab therapy with your patient and document the discussion in patient's record.
- To place a referral:
 - From outside HHP, send an email to Dr. Sandra Noon (<u>sandra.noon@hphmg.org</u>) with the subject:
 Sotrovimab Administration Request.
 - From within HHP, please place a MoAb Treatment Request from the HHP intranet home page
- Please inform patients Sotrovimab is in limited supply and that we cannot guarantee they will receive it.



Referrals for MoAb

HHP/HPH Community Webinar Series (CME 8/25/2021 12:00 PM & OPP/SSP Credit)

COVID-19 UPDATES/ MEMOS



COVID-19 Vaccination Requirement:

- Employee CDVID Vaccine Policy twovember 2021
- COVID 19 Vaccine Requirement FAQs November 2021
- Tasting Protocol October 2021
- COVID Vaccination and Testing Requirements Flowchart October 2021

FAQs:

- COVID-19 Vaccine FAQs
- COVID-19 Vaccine FAQs for Managers
- COVID Convelescent Plasma (CCP) August 10, 2020
- Employee Health Reminders.
- FAQs for HPH Employees
- · FINDS for HIPH Manager
- Filidas for Employees Working from Home
- RACs Patient Privacy Related to COVID-18
- HPH Travel Protocol Effective 10/20/21
- Return to Work January 7, 2022
- Working ?sigether Microsoft Teams and O345

Self-Care


Leadership Resources

For Patients:

- Multilingual Resources (scroll down in this DOH alte for handouts)
- Stay Healthy And Informed With Hills
- · What to do after you are terred for CDVID-19

COVID-19 Response Plan

COVID-19 VACCINE - Patient Information for Providers and Employees: COVID-19 Testing/Vaccination Appointment Self-Scheduler



Latest HPH COVID-19 Bulletins & Information (previous Bulletins in archives).

McAb Treatment Request

- Epic infection/solation Baimer and MyChart Home Monitoring Tip Sheet August 23, 2021
- DOH COVID-19 Update #20 Quarantine Guidance for Vaccinated Persons Following Exposure Feb 11, 2021.
- Bulletin #436 January 12, 2022
- CLH COVID-19 Technical Bulletin Melecular Revision May 19, 2020
- Visitor Policy Update and Buidelines on Mails October 15, 2021
- COVID-19 Hawari Cases (anually 12, 2022)
- Beyond COVID 19: Concept Model & indicators May 13, 2020
- Beyond COVID 19k Reopening Status Update
- HPH Surge Plan: KMCWC, PMMC, SMC, WMC

Clinical/Workflow Algorithms and Specimen Collection:

- COVID-19 Algorithms:
- Specimen Collection:
- Ambulatory COVID Monitoring Program.
- Isolation Code Blue Process:

Airway Management:

Instrument/Medical Device Inspection Resources:

PPE Guidelines:

PPE Donning and Doffing:

PPE & Medical Equipment Cleaning and Conservation:


COVID-19 Therapeutics (HPH):

COVID-19 Inpatient Vaccination Resources:

Advance Care Planning Scripting:

411 PALIFIL PARTNERS HEALTH

Covid Treatment Tier Algorithm



CREATING A HEALTHIER HAWAI'I

HAWAI'I

HEALTH PARTNERS

HAWAI'I

PACIFIC

HEALTH

Outpatient COVID-19 Treatment: Patient Risk Stratification - Criteria

Immunocompromised individuals

- Patients who are within 1 year of receiving B-cell depleting therapies (e.g., rituximab, ocrelizumab, ofatumumab, alemtuzumab)
- Patients receiving Bruton tyrosine kinase inhibitors
- Chimeric antigen receptor T cell recipients
- Post-hematopoietic cell transplant recipients who have chronic graft versus host disease or who are taking immunosuppressive medications for another indication
- Patients with hematologic malignancies who are on active therapy
- Lung transplant recipients
- Patients who are within 1 year of receiving a solid-organ transplant (other than lung transplant)
- Solid-organ transplant recipients with recent treatment for acute rejection with T or B cell depleting agents
- Patients with severe combined immunodeficiencies
- Patients with untreated HIV who have a CD4 T lymphocyte cell count <50 cells/mm3

Medical conditions for high risk progression to severe COVID-19

 Adults with BMI >25 kg/m2, or if 12 to 17 years of age, have BMI ≥85th percentile for their age and gender based on CDC growth charts,

https://www.cdc.gov/growthcharts/clinical_charts.html)

- Pregnancy
- Chronic kidney disease III or higher
- Diabetes
- Cardiovascular disease (including congenital heart disease) or hypertension
- Chronic lung diseases (for example, chronic obstructive pulmonary disease, asthma [moderate-to-severe], interstitial lung disease, cystic fibrosis and pulmonary hypertension)
- Sickle cell disease
- Neurodevelopmental disorders (for example, cerebral palsy) or other conditions that confer medical complexity (for example, genetic or metabolic syndromes and severe congenital anomalies)
- Having a medical-related technological dependence (for example, tracheostomy, gastrostomy, or positive pressure ventilation [not related to COVID 19])



HPH Policies and Updates



Melinda Ashton, MD Executive Vice President and Chief Quality Officer Hawai'i Pacific Health



Shilpa Patel, MD Associate Chief Quality Office Hawai'i Pacific Health

HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS

Work Restrictions for HCP With SARS-CoV-2 Infection and Exposures

HCP are considered "boosted" if they have received all COVID-19 vaccine doses, including a booster dose, as recommended by CDC. HCP are considered "vaccinated" or "unvaccinated" if they have NOT received all COVID-19 vaccine doses, including a booster dose, as recommended by CDC.

For more details, including recommendations for healthcare personnel who are immunocompromised, refer to Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2 (conventional standards) and Strategies to Mitigate Healthcare Personnel Staffing Shortages (contingency and crisis standards).

Work Restrictions for HCP With SARS-CoV-2 Infection

negative test

Vaccination Status	Conventional	Contingency	Crisis
Boosted, Vaccinated, or Unvaccinated	10 days OR 7 days with negative test ⁺ , if asymptomatic or mildly symptomatic (with improving symptoms)	5 days with/without negative test, if asymptomatic or mildly symptomatic (with improving symptoms)	No work restriction, with prioritization considerations (e.g., asymptomatic or mildly symptomatic)
/ork Restrictions for Asym	ptomatic HCP with Exposi	ures	
Vaccination Status	Conventional	Contingency	Crisis
Vaccination Status Boosted	Conventional No work restrictions, with negative test on days 2 [‡] and 5–7	Contingency No work restrictions	Crisis No work restrictions

tests on days 1[‡], 2, 3, & 5-7

Vaccinated or Unvaccinated, even if within 90 days of prior infection

†Negative test result within 48 hours before returning to work

*For calculating day of test: 1) for those with infection consider day of symptom onset (or first positive test if asymptomatic) as day 0; 2) for those with exposure consider day of exposure as day 0



CS128856-A | December 23, 2021 5-27 PM

cdc.gov/coronavirus





Q&A

Sarah Kemble, MD

State Epidemiologist,

Hawai'i State Department of Health



CREATING A HEALTHIER HAWAI'I

HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS



Thank you!

- A recording of the meeting will be available afterwards.
- Unanswered question?
 - Contact us at <u>Covid19Bulletin@hawaiipacifichealth.org</u>

CREATING A HEALTHIER HAWAI'I

HAWAI'I PACIFIC HEALTH

HAWAI'I HEALTH PARTNERS